Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Cdnmate23on Jun 09, 2020 8:19pm

197 Views

Post# 31131266

RE:RE:RE:RE:RE:Insider Trading complaint

Hoping a regulator will look into these shenanigans is a low probability wish.

Class action is the way to go. Imagine these smug pricks patting each other on the back and having a laugh at successful execution of a deceitfully planned scheme to help themselves and underwriters, knowingly at the expense of long term holders. If you want cheap shares again, launch a suit and get that headline published.

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment